[1]

Amounts may not add due to rounding.

[2]

Income from continuing operations before provision for taxes on income.

[3]

Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, which in 2015 includes the revenues and expenses related to our transitional manufacturing and supply agreements with Zoetis. Other business activities also includes the costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

[4]

For a description, see the “Other Costs and Business Activities” section above.

[5]

Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.For Revenues in the second quarter and first six months of 2014, certain significant items represents revenues related to our transitional manufacturing and supply agreements with Zoetis, Inc. (Zoetis). For additional information, see Notes to Consolidated Financial Statements––Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures included in our 2014 Financial Report, which was filed as Exhibit 13 to our 2014 Annual Report on Form 10-K. For Earnings in the second quarter of 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $91 million, (ii) charges for certain legal matters of $92 million, (iii) charges for business and legal entity alignment of $63 million and (iv) other charges of $58 million. For additional information, see Note 3 and Note 4.For Earnings in the second quarter of 2014, certain significant items includes: (i) charges for certain legal matters of $4 million, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $212 million, (iii) charges for business and legal entity alignment of $39 million and (iv) other income of $17 million. For additional information, see Note 3 and Note 4.For Earnings in the first six months of 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $195 million, (ii) charges for business and legal entity alignment of $164 million, (iii) charges for certain legal matters of $92 million and (iv) other charges of $81 million. For additional information, see Note 3 and Note 4.For Earnings in the first six months of 2014, certain significant items includes: (i) charges for certain legal matters of $698 million, (ii) certain asset impairments of $114 million, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $346 million, (iv) charges for business and legal entity alignment of $67 million and (v) other charges of $29 million. For additional information, see Note 3 and Note 4.